{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-23-000068","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.723721+00:00","generated_at":"2026-06-08T06:43:22.485576+00:00","sec_items":["1.01","2.02","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Recursion posts Q3 net loss $93M, inks $160M Tempus data deal, restructures Bayer collaboration for oncology","bullets":["Q3 net loss of $93.0M vs $60.4M prior year; revenue $10.5M down from $13.2M.","Tempus 5-year data licensing deal: annual payments $22M-$42M (up to $160M total) for 20+ PB oncology data.","Bayer collaboration refocused on oncology; up to 7 programs with aggregate milestones up to $1.5B plus royalties.","BioHive-1 supercomputer to quadruple compute with NVIDIA H100 GPUs, expected top 50 globally by H1 2024.","Cash $387.3M at Sept 30; pipeline on track with Phase 2 CCM and NF2 data expected H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-23-000068","json":"https://secwatch.observer/filing/0001601830-23-000068.json","markdown":"https://secwatch.observer/filing/0001601830-23-000068.md","text":"https://secwatch.observer/filing/0001601830-23-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/rxrx-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:43:22.485576+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6b102b2bf088ad18e7c00b92b920307315517cb4","claim":"RECURSION PHARMACEUTICALS, INC. reported financial results for the third quarter ending September 30, 2023.","evidence_excerpt":"On November 9, 2023, the Company issued a press release announcing its results of operations and financial condition for the third quarter September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ending September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8a8d73b6014a0b1140a25caa499833f600ae5f49","claim":"RECURSION PHARMACEUTICALS, INC. amended Restated Bayer Agreement with Bayer AG valued at Amendment and restatement of the Original Research Collaboration and Option Agreement to re-align wi (effective 2023-11-08).","evidence_excerpt":"On November 8, 2023, the parties amended and restated the Original Bayer Agreement (the “Restated Agreement”) to re-align the Original Agreement with Bayer’s strategic shift in focus to oncology, as further described below.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Bayer AG"},{"label":"Value","value":"Amendment and restatement of the Original Research Collaboration and Option Agreement to re-align wi"},{"label":"Effective","value":"2023-11-08"}],"fact_type":"material_agreement"},{"claim_id":"d5ec6c23336c4e4d2714149942b345970fbdbd38","claim":"RECURSION PHARMACEUTICALS, INC. entered into Tempus Master Agreement with Tempus Labs, Inc. valued at Initial license fee of $22.0 million; annual fees ranging from $22.0 million to $42.0 million; total (effective 2023-11-03).","evidence_excerpt":"On November 3, 2023, Recursion Pharmaceuticals, Inc. (the “Company”) and Tempus Labs, Inc. (“Tempus”) entered into a Master Agreement (the “Tempus Agreement”) pursuant to which Tempus may provide certain services and deliverables to Company and/or license certain data to Company.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1601830/000160183023000068/0001601830-23-000068-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"Tempus Labs, Inc."},{"label":"Value","value":"Initial license fee of $22.0 million; annual fees ranging from $22.0 million to $42.0 million; total"},{"label":"Effective","value":"2023-11-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}